Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo

Oncogenesis

Volumn 1, Issue 5, 2012, Pages

  Miah, S ^a   Martin, A ^a   Lukong, K E ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

breast cancer; breast tumor kinase; BRK; PTK6; tumor formation; xenograft

Indexed keywords

BREAST TUMOR KINASE; ENZYME VARIANT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

EID: 84868282534     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.11     Document Type: Article

References (49)

1. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15: 799-805. (Pubitemid 27390132)
2. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ et al. Cloning and characterization of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994; 9: 2383-2390. (Pubitemid 24228691)
3. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007; 96: 801-807. (Pubitemid 46376621)
4. Mitchell PJ, Barker KT, Shipley J, Crompton MR. Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene 1997; 15: 1497-1502. (Pubitemid 27437840)
5. Harvey AJ, Pennington CJ, Porter S, Burmi RS, Edwards DR, Court W et al. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol 2009; 175: 1226-1234.
6. Easty DJ, Mitchell PJ, Patel K, Flørenes VA, Spritz RA, Bennett DC. Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer 1997; 71: 1061-1065. (Pubitemid 27252891)
7. Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999; 5: 1767-1777. (Pubitemid 29334458)
8. Petro BJ, Tan RC, Tyner AL, Lingen MW, Watanabe K. Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol 2004; 40: 1040-1047. (Pubitemid 39422790)
9. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22: 4212-4220. (Pubitemid 36876242)
10. Kasprzycka M, Majewski M, Wang ZJ, Ptasznik A, Wysocka M, Zhang Q et al. Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. Am J Pathol 2006; 168: 1631-1641.
11. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR et al. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 2006; 5: 1136-1141. (Pubitemid 44772228)
12. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 2003; 13: 409-419. (Pubitemid 38166373)
13. Derry JJ, Richard S, Carvajal HV, Ye X, Vasioukhin V, Cochrane AW et al. Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding activity. Mol Cell Biol 2000; 20: 6114-6126. (Pubitemid 30613059)
14. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002; 277: 34634-34641.
15. Okada M, Nakagawa H. A protein tyrosine kinase involved in regulation of pp60csrc function. J Biol Chem 1989; 264: 20886-20893. (Pubitemid 20017891)
16. Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta 2003; 1653: 73-86. (Pubitemid 37487649)
17. Lukong KE, Larocque D, Tyner AL, Richard S. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem 2005; 280: 38639-38647. (Pubitemid 43853766)
18. Qiu H, Miller WT. Role of the Brk SH3 domain in substrate recognition. Oncogene 2004; 23: 2216-2223. (Pubitemid 38482536)
19. Kim H, Jung J, Lee ES, Kim YC, Lee W, Lee ST. Molecular dissection of the interaction between the SH3 domain and the SH2-kinase linker region in PTK6. Biochem Biophys Res Commun 2007; 362: 829-834. (Pubitemid 47390648)
20. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ et al. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271: 30956-30963. (Pubitemid 26404123)
21. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004; 24: 10558-10572.
22. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008; 65: 3525-3544.
23. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003; 22: 5006-5010. (Pubitemid 37026399)
24. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007; 67: 4199-4209. (Pubitemid 46815066)
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747)
26. Tsatsanis C, Spandidos DA. Oncogenic kinase signaling in human neoplasms. Ann NY Acad Sci 2004; 1028: 168-175. (Pubitemid 40361821)
27. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-185.
28. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6: 229-239. (Pubitemid 39440251)
29. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6-BRK by BRK. Biochim Biophys Acta 2010; 1806: 66-73.
30. Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010; 9: 1854-1863.
31. Hunter T. A tail of two src's: mutatis mutandis. Cell 1987; 49: 1-4.
32. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918-7927. (Pubitemid 39468851)
33. Kmiecik TE, Shalloway D. Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell 1987; 49: 65-73.
34. Piwnica-Worms H, Saunders KB, Roberts TM, Smith AE, Cheng SH. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell 1987; 49: 75-82.
35. Pallen CJ. Protein tyrosine phosphatase alpha (PTPalpha): a Src family kinase activator and mediator of multiple biological effects. Curr Top Med Chem 2003; 3: 821-835.
36. Elsberger B, Tan BA, Mallon EA, Brunton VG, Edwards J. Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. Br J Cancer 2010; 103: 1831-1834.
37. Lukong KE, Huot ME, Richard S. BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest. Cell Signal 2009; 21: 1415-1422.
38. Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 2006; 18: 753-760. (Pubitemid 43208930)
39. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384-388. (Pubitemid 30620293)
40. Seton-Rogers SE, Lu Y, Hines LM, Koundinya M, LaBaer J, Muthuswamy SK et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004; 101: 1257-1262. (Pubitemid 38182676)
41. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ et al. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271: 30956-30963. (Pubitemid 26404123)
42. Li X, Lu Y, Liang K, Hsu J-M, Albarracin C, Mills GB et al. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene (e-pub ahead of print 9 January 2012; doi:10.1038/onc.2011. 608).
43. Kim H, Lee ST. An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6. J Biol Chem 2005; 280: 28973-28980. (Pubitemid 41161344)
44. Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML et al. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res 2008; 68: 7779-7787.
45. Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL et al. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res 2011; 13: R89.
46. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358. (Pubitemid 36791891)
47. Elsberger B, Stewart B, Tatarov O, Edwards J. Is Src a viable target for treating solid tumours? Curr Cancer Drug Targets 2010; 10: 683-694.
48. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268. (Pubitemid 36677560)
49. Geback T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 2009; 46: 265-274.